Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

Büller, Harry R; Prins, Martin H; Lensing, Anthonie W A; Decousus, Hervé; Jacobson, Barry F; Minar, Erich; Chlumsky, Jaromir; Verhamme, Peter; Wells, Phil; Agnelli, Giancarlo; Cohen, Alexander; Berkowitz, Scott D; Bounameaux, Henri; Davidson, Bruce L; Misselwitz, Frank; Gallus, Alex S; Raskob, Gary E; Schellong, Sebastian; Segers, Annelise

doi:10.1056/NEJMoa1113572

Scientific article

English

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

ContributorsBüller, Harry R; Prins, Martin H; Lensing, Anthonie W A; Decousus, Hervé; Jacobson, Barry F; Minar, Erich; Chlumsky, Jaromir; Verhamme, Peter; Wells, Phil; Agnelli, Giancarlo; Cohen, Alexander; Berkowitz, Scott D; Bounameaux, Henri; Davidson, Bruce L; Misselwitz, Frank; Gallus, Alex S; Raskob, Gary E; Schellong, Sebastian; Segers, Annelise

Published inThe New England journal of medicine, vol. 366, no. 14, p. 1287-1297

Publication date2012

Abstract

A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.

Keywords

Administration
Oral
Aged
Anticoagulants/adverse effects/therapeutic use
Drug Therapy
Combination
Enoxaparin/adverse effects/therapeutic use
Female
Follow-Up Studies
Hemorrhage/chemically induced
Humans
International Normalized Ratio
Kaplan-Meier Estimate
Male
Middle Aged
Morpholines/adverse effects/therapeutic use
Pulmonary Embolism/drug therapy/mortality
Recurrence
Thiophenes/adverse effects/therapeutic use
Treatment Outcome
Vitamin K/antagonists & inhibitors

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Citation (ISO format)

BÜLLER, Harry R et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. In: The New England journal of medicine, 2012, vol. 366, n° 14, p. 1287–1297. doi: 10.1056/NEJMoa1113572

Article (Published version)

Identifiers

PID : unige:26316
DOI : 10.1056/NEJMoa1113572
PMID : 22449293

Journal ISSN0028-4793

4410views

5094downloads

Creation10/11/2012 9:59:00 AM

First validation10/11/2012 9:59:00 AM

Update time02/03/2025 11:36:19 AM

Status update02/03/2025 11:36:19 AM

Last indexation02/03/2025 11:41:52 AM

Archive ouverte UNIGE

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.

Technical informations